Risk Factors of Treatment Failure in Antibody Mediated Rejection.

V. Pernin,¹ I. Szwarc,¹ T. Kanouni,² V. Garrigue,¹ J. Serre,¹ S. Delmas,¹ G. Mourad,¹ M. Le Quintrec.¹

¹Department of Nephrology, Dialysis and Transplantation, CHU Lapeyronie, Montpellier, France
²Department of Hematology, CHU St ELoi, Montpellier, France

Meeting: 2017 American Transplant Congress

Abstract number: A5

Keywords: Graft failure, Kidney transplantation, Outcome, Rejection

Session Information

Session Name: Poster Session A: Antibody Mediated Rejection in Kidney Transplant Recipients I

Session Type: Poster Session

Date: Saturday, April 29, 2017

Session Time: 5:30pm-7:30pm

Presentation Time: 5:30pm-7:30pm

Location: Hall D1

Background: Antibody-mediated rejection (AMR) is recognized as the major cause of kidney allograft loss. Despite an aggressive treatment, prognosis is usually poor. The aim of our study was to analyze the graft survival and the risk factors of treatment failure in AMR.

Methods: Patient with AMR were selected between 01/03/2011 and 02/11/2015 according to Banff classification. Recipients characteristics, renal function, proteinuria, immunodominant DSA (DSAi), histologic lesions on transplant biopsy and the modality of treatment were recorded. Treatment failure was defined as a decrease of GFR>25% or graft loss 12 months after treatment of AMR.

Result: 43 patients developed an AMR with a median time after transplantation were 4.7±4.4 years. DSA were preformed for 5 patients and de novo for 38 patients. At diagnosis (D0), mean serum creatinine was 214+/-102[micro]mol/L, mean GFR (MDRD) was 33.9±14.3ml/min/1.73m², and the ratio proteinuria/ creatininuria was 1.05+/-1.46g/g. All patients received plasma exchange (n=36) or Protein A immunoadsorption (n=7) with a mean number of sessions of 8.3. Twenty-one patients (48.8%) received high dose IVIG, and 28 patients (65.1%) received Rituximab (1 or 2 infusions at 375mg/m²). Graft survival at 1 year was 86%. Sixteen patients presented a treatment failure: graft loss (n = 6) or decrease in GFR> 25% (n = 10).

Risk factors associated with treatment failure in univariate analysis were, at D0 : cg score (HR: 2.1, p=0.001), mm score (HR: 3.6, p = 0.001), and tubular atrophy (ct) (HR: 2.24, P=0.03) and, during follow-up : deterioration of GFR between D0-M3 (HR: 0.93, p = 0.01), proteinuria at M3 (HR 1.01, p=0.001), and the evolution of the MFI for DSAi between D0-M3 (HR: 1.01, p=0.05). In multivariate analysis, only mesangial hypertrophy at diagnosis (mm score) and the evolution of the MFI for DSAi between D0-M3 were associated with treatment failure.

The score of mesangial hypertrophy (mm) and the evolution of the MFI for DSAi between D0-M3 are the only independent risk factors of AMR treatment failure.

CITATION INFORMATION: Pernin V, Szwarc I, Kanouni T, Garrigue V, Serre J, Delmas S, Mourad G, Le Quintrec M. Risk Factors of Treatment Failure in Antibody Mediated Rejection. Am J Transplant. 2017;17 (suppl 3).

To cite this abstract in AMA style:

Pernin V, Szwarc I, Kanouni T, Garrigue V, Serre J, Delmas S, Mourad G, Quintrec MLe. Risk Factors of Treatment Failure in Antibody Mediated Rejection. [abstract]. Am J Transplant. 2017; 17 (suppl 3). https://atcmeetingabstracts.com/abstract/risk-factors-of-treatment-failure-in-antibody-mediated-rejection/. Accessed November 22, 2024.

« Back to 2017 American Transplant Congress